Shigellosis - Pipeline Insight, 2024

Shigellosis - Pipeline Insight, 2024

DelveInsight’s, “Shigellosis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Shigellosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Shigellosis Understanding

Shigellosis: Overview

Shigellosis is a bacterial infection caused by a group of bacteria called Shigella. It affects the digestive system. Shigella is very contagious and spread through contaminated water and food or via contact with contaminated feces. The bacteria release toxins that irritate the intestines. The primary symptom of shigellosis is diarrhea. Shigella are usually found in the feces of infected people. The bacteria are spread when someone comes into contact with the stool of an infected person, or with something that has been contaminated with the stool or the bacteria. Contaminated food and water are also a common cause of shigellosis. The main goal of treatment is preventing dehydration for most cases of shigellosis. Treatment usually includes antibiotics to eliminate the bacteria from the digestive tract.

""Shigellosis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Shigellosis pipeline landscape is provided which includes the disease overview and Shigellosis treatment guidelines. The assessment part of the report embraces, in depth Shigellosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Shigellosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Shigellosis R&D. The therapies under development are focused on novel approaches to treat/improve Shigellosis.

Shigellosis Emerging Drugs Chapters

This segment of the Shigellosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Shigellosis Emerging Drugs

• Shigella 4v: GlycoVaxyn

It is a biconjugate (Tetravalent) vaccine. Currently, in phase II of clinical trials for the treatment of shigella infection.

• SF2a-TT15: Institut Pasteur

A synthetic carbohydrate-based Shigella flexneri 2a vaccine candidate.

Further product details are provided in the report……..

Shigellosis: Therapeutic Assessment

This segment of the report provides insights about the different Shigellosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Shigellosis

There are approx. 5+ key companies which are developing the therapies for Shigellosis. The companies which have their Shigellosis drug candidates in the mid to advanced stage, i.e. Phase II include, GlycoVaxyn and others.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase II/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Shigellosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Parenteral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptides
• Polymer
• Gene Therapy
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Shigellosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Shigellosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Shigellosis drugs.

Shigellosis Report Insights

• Shigellosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Shigellosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Shigellosis drugs?
• How many Shigellosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Shigellosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Shigellosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Shigellosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlycoVaxyn
• Institut Pasteur
• GlaxoSmithKline

Key Products

• SF2a-TT15
• Shigella 4v
• 1790GAHB vaccine